A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 169, Issue 5, Pages 694-700
Publisher
Wiley
Online
2015-03-30
DOI
10.1111/bjh.13353
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment with FLT3 inhibitor in patients withFLT3-mutated acute myeloid leukemia is associated with development of secondaryFLT3-tyrosine kinase domain mutations
- (2014) Yesid Alvarado et al. CANCER
- Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia
- (2014) Jeffery M. Klco et al. CANCER CELL
- The evolving molecular genetic landscape in acute myeloid leukaemia
- (2013) Mathijs A. Sanders et al. CURRENT OPINION IN HEMATOLOGY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
- (2012) B. Parkin et al. BLOOD
- Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
- (2012) Krzysztof Mrózek et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
- (2012) A B Williams et al. LEUKEMIA
- The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse
- (2012) C Bachas et al. LEUKEMIA
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- (2012) R M Stone et al. LEUKEMIA
- Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
- (2012) A S Moore et al. LEUKEMIA
- A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
- (2012) David A. Macdonald et al. LEUKEMIA & LYMPHOMA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
- (2009) S. Metzelder et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More